Agencies-Gaza post
Marketing of the first China’s artificial heart
China agreed to market the first artificial heart “Implantable Left Ventricle Assistance System”, which has fully independent intellectual property rights developed by Tayshin Space Technology Co., Ltd., Tianjin on July 13.
Ventricular aids are the most effective treatment for heart failure except for heart transplants according to Shenhua.
The heart is characterized by its small size, lightweight, high temperature, good hemolytic dissolution, and stable quality.
The heart is the country’s first left implantable ventricular assist system with magnetohydrodynamic levitation technologies, according to the website of the administration.
According to a press statement issued by the TEDA, the assist system was also the first artificial heart produced domestically in China that had successfully completed 50 cases of clinical testing and fully complied with all guidelines and conditions established by the administration for such trials.
“Over the past 13 years, the teams of the hospital and the academy have jointly devoted themselves to the research and development by a combination of medicine and engineering, and have obtained detailed data and rich experiences,” said Liu Xiaocheng, the principal investigator of the clinical trial project and the president of TEDA International Cardiovascular Hospital.
This entirely domestic artificial heart is anticipated to put an end to the myth that China cannot treat advanced heart failure and bring relief to Chinese patients with severe heart failure and their families, he said.
